
## SUPPLEMENTARY FIGURE



**Supplementary Figure 1. Clinical features of the patient from whom CWH22 and CLM22 organoids were derived.** (A) CT (venous phase) and MRI (T2-weighted) scans of lesions on the left lobe of the liver (scale bars, 5 cm). (B) Image of the space-occupying lesion in the ascending colon under colonoscopy. (C) H&E and IHC staining used for histological diagnosis. Scale bars, 100 µm. (D) Timeline of treatments administered to the patient and treatment response records (PD: progressive disease; PR: partial response; CR: complete response). (E) Representative MR images of the liver at different treatment response time points. (F) Serum CEA levels during the treatment period from January 2021 to November 2022, reflecting the treatment response.